Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jul 1;64(7):4125-4132.
doi: 10.1093/rheumatology/keaf146.

A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis

Elie Naddaf  1 , Michael P Skolka  2 , Larry Prokop  3 , Mazen M Dimachkie  4 , Jean-Yves Hogrel  5 , Olivier Benveniste  6 , Zhen Wang  7   8 , Jay Mandrekar  9 , Colin P West  9   10 , M Hassan Murad  7   8
Affiliations
Meta-Analysis

A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis

Elie Naddaf et al. Rheumatology (Oxford). .

Abstract

Objectives: IBM is characterized by slowly progressive muscle weakness making it challenging to detect significant changes in weakness during a clinical trial. Trial participants receiving placebo may behave differently from in natural history studies. We aimed to quantify the change in muscle strength and IBM Functional Rating Scale (IBMFRS) of IBM patients receiving placebo during clinical trials.

Methods: Several databases were searched. Randomized, double-blinded, placebo-controlled trials without treatment intervention on the placebo group were included. Standardized mean differences (SMD) for change in muscle strength and mean differences for IBMFRS were used to calculate pooled effects, using DerSimonian-Laird continuous random effect models. Meta-regression determined change in muscle strength. Heterogeneity was evaluated using the I2 indicator.

Results: Eleven eligible trials were identified with 257 participants receiving placebo and a low risk of bias per the Cochrane Collaboration Risk of Bias 2 (RoB2) tool. Participants receiving placebo on average had a measurable decline in muscle strength with a mean effect size of -0.398 (95% CI -0.652, -0.144) (P = 0.002). SMD changed by -0.009 (-0.016, -0.002) points per week (P = 0.015). Manual muscle testing was associated with higher heterogeneity (I2 = 67.68%) compared with quantitative muscle testing (I2 = 0%). Only three studies reported IBMFRS results. The pooled change in IBMFRS at 12 months was -2.189 points (-3.893, -0.485) on this 0 to 40-point scale (P = 0.012), with relatively high heterogeneity.

Conclusion: Participants with IBM displayed a measurable decline in their muscle strength and IBMFRS during clinical trials, in keeping with the disease's slowly progressive nature. These estimates can inform sample size calculations in future studies.

Keywords: inclusion body myositis; meta-analysis; placebo response; systematic review.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Benveniste O, Guiguet M, Freebody J et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176–84. - PubMed
    1. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000;55:296–8. - PubMed
    1. Naddaf E, Shelly S, Mandrekar J et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford, England) 2022;61:2016–24. - PMC - PubMed
    1. Roy B, Lucchini M, Lilleker JB et al. ; International Myositis Assessment and Clinical Studies (IMACS) Inclusion Body Myositis Scientific Interest Group. Current status of clinical outcome measures in inclusion body myositis: a systematised review. Clin Exp Rheumatol 2023;41:370–8. - PubMed
    1. Skolka MP, Naddaf E. Exploring challenges in the management and treatment of inclusion body myositis. Curr Opin Rheumatol 2023;35:404–13. - PMC - PubMed

MeSH terms

LinkOut - more resources